Post hoc analysis shows brexpiprazole improves agitation in dementia patients, highlighting treatment safety.
Objective To explore the efficacy and safety of brexpiprazole for the treatment of agitation symptoms in clinically relevant subgroups of patients with dementia due to Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Stroud et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: